Stockreport

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned Initiated Development of Hypoimmune iPSC Cell Line for Neurology Indications Under Gene Ed [Read more]